Beam plans to utilize an 'umbrella' clinical trial design, allowing multiple mutation-specific base editors to be developed ...

Beam Therapeutics Inc. (NASDAQ:BEAM) on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) at the 2025 Alpha-1 ...

Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a ...

First Patient Dosed in the Phase 1/2 Study of BEAM-301 in Glycogen Storage Disease Type Ia, Beam’s Second Clinical Stage In Vivo Editing Program Updated Data from BEACON Phase 1/2 Clinical Trial of ...

Detailed price information for Beam Therapeutics Inc (BEAM-Q) from The Globe and Mail including charting and trades.

We expect investors to focus on Beam Therapeutics’ BEAM progress in developing its pipeline candidates, which are being studied for hematological and immuno-oncology indications, when it reports first ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the best gene-editing stocks to buy according to hedge funds. On November 14, Beam Therapeutics Inc. (NASDAQ:BEAM) announced Q3 2025 results in which it ...

During the last three months, 4 analysts shared their evaluations of Beam Therapeutics (NASDAQ:BEAM), revealing diverse outlooks from bullish to bearish. The following table encapsulates their recent ...